| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8507667 | Acta Pharmaceutica Sinica B | 2018 | 11 Pages |
Abstract
Downstream ERK kinase appears to be the Achilles' Heel of the MAPK pathway. Targeting ERK kinase provides potential therapeutic opportunities for a broad spectrum of cancers bearing RAS, RAF and MEK mutations as well as those with acquired resistance to BRAF and MEK inhibitors (RAFi and MEKi).109
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Feifei Liu, Xiaotong Yang, Meiyu Geng, Min Huang,